EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Seres Therapeutics's enterprise value is $170.5 Mil.
Seres Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-94.3 Mil. Therefore, Seres Therapeutics's EV-to-EBITDA for today is -1.81.
The historical rank and industry rank for Seres Therapeutics's EV-to-EBITDA or its related term are showing as below:
MCRB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.87 Med: -3.03 Max: -0.42
Current: -1.81
During the past 12 years, the highest EV-to-EBITDA of Seres Therapeutics was -0.42. The lowest was -32.87. And the median was -3.03.
MCRB's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs MCRB: -1.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Seres Therapeutics's stock price is $0.6246.
Seres Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.900. Therefore, Seres Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Seres Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Seres Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Seres Therapeutics Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-3.09
-25.47
-9.24
-2.87
-2.92
Seres Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-2.87
-3.08
-4.31
-2.81
-2.92
Competitive Comparison
For the Biotechnology subindustry, Seres Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seres Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Seres Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Seres Therapeutics's EV-to-EBITDA falls into.
Seres Therapeutics EV-to-EBITDA Calculation
Seres Therapeutics's EV-to-EBITDA for today is calculated as:
Seres Therapeutics's current Enterprise Value is $170.5 Mil.
Seres Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-94.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Seres Therapeutics's PE Ratio for today is calculated as:
Seres Therapeutics's share price for today is $0.6246.
Seres Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Seres Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Seres Therapeutics (Seres Therapeutics) Business Description
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCRB has been successfully added to your 